| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/22/2004 | CA2493111A1 Diagnosis and prevention of cancer cell invasion |
| 01/22/2004 | CA2492772A1 Activated checkpoint therapy and methods of use thereof |
| 01/22/2004 | CA2492673A1 Heterobicyclic pyrazole derivatives as kinase inhibitors |
| 01/22/2004 | CA2492559A1 Mcam inhibitors |
| 01/22/2004 | CA2492485A1 Stable pharmaceutical composition comprising erythropoietin |
| 01/22/2004 | CA2492427A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | CA2492421A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | CA2492355A1 Method for diagnosis of intestinal-type gastric tumors |
| 01/22/2004 | CA2492330A1 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 01/22/2004 | CA2492297A1 Steroid conjugates, preparation thereof and the use thereof |
| 01/22/2004 | CA2492273A1 3, 10, and 12a substituted tetracycline compounds |
| 01/22/2004 | CA2492175A1 Combination of chemotherapeutic drugs for increasing antitumor activity |
| 01/22/2004 | CA2492164A1 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | CA2492100A1 Substituted 2-alkylamine nicotinic amide derivatives and use there of |
| 01/22/2004 | CA2492083A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 01/22/2004 | CA2492059A1 Combinations of drugs for the treatment of neoplasms |
| 01/22/2004 | CA2492046A1 Benzamide or phenylacetamide derivatives useful as thyroid receptor ligands |
| 01/22/2004 | CA2492045A1 Substituted amine derivatives and methods of use |
| 01/22/2004 | CA2491917A1 Altered insulin-like growth factor binding proteins |
| 01/22/2004 | CA2491661A1 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 01/22/2004 | CA2491655A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 01/22/2004 | CA2491422A1 Novel macrocycles for the treatment of cancer diseases |
| 01/22/2004 | CA2491191A1 Receptor-type kinase modulators and methods of use |
| 01/22/2004 | CA2491183A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 01/22/2004 | CA2491077A1 Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders |
| 01/22/2004 | CA2490818A1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/22/2004 | CA2489790A1 3-furanyl analogs of toxoflavine as kinase inhibitors |
| 01/21/2004 | EP1382969A1 Diagnosis and prevention of cancer cell invasion |
| 01/21/2004 | EP1382615A1 MCAM inhibitors |
| 01/21/2004 | EP1382607A2 Prenyl transferase inhibitors |
| 01/21/2004 | EP1382604A1 Quinoline derivative having azolyl group and quinazoline derivative |
| 01/21/2004 | EP1382603A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF |
| 01/21/2004 | EP1382350A1 Preventives for postoperative recurrence of premenopausal breast cancer |
| 01/21/2004 | EP1382349A1 Supplementary immunotherapeutics to be used after lung cancer removal |
| 01/21/2004 | EP1382346A1 Conditioned medium and diffusible biological product produced by incubating entrapped cells |
| 01/21/2004 | EP1382343A1 Combination therapy to treat hepatitis B virus |
| 01/21/2004 | EP1382339A1 Compositions containing pyrrolo [2,3-d] pyrimidine derivatives |
| 01/21/2004 | EP1382332A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent |
| 01/21/2004 | EP1381867A2 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls |
| 01/21/2004 | EP1381839A2 Method of imaging cell death in vivo |
| 01/21/2004 | EP1381691A2 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression |
| 01/21/2004 | EP1381684A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/21/2004 | EP1381683A2 Human fibroblast growth factor-related compositions |
| 01/21/2004 | EP1381678A2 Nucleic acid modification enzymes |
| 01/21/2004 | EP1381674A2 Method for generating highly active human dendritic cells from monocytes |
| 01/21/2004 | EP1381631A2 Human timp-1 antibodies |
| 01/21/2004 | EP1381630A2 Vhh single heavy chain antibody and a method for its preparation in a mammal |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381611A1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381599A1 Quinazoline derivatives |
| 01/21/2004 | EP1381598A1 Novel tyrosine kinase inhibitors |
| 01/21/2004 | EP1381591A2 Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors |
| 01/21/2004 | EP1381590A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 01/21/2004 | EP1381432A2 Hsa-free formulations of interferon-beta |
| 01/21/2004 | EP1381408A2 Modular infusion device and method |
| 01/21/2004 | EP1381391A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto |
| 01/21/2004 | EP1381387A2 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases |
| 01/21/2004 | EP1381384A2 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFa |
| 01/21/2004 | EP1381378A1 Compositions and methods for cancer prevention and treatment derived from inula britannica |
| 01/21/2004 | EP1381375A2 Oligonucleotide compositions and their use to induce differentiation of cells |
| 01/21/2004 | EP1381373A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381360A1 Compounds and methods for inhibiting metap2 in mammals |
| 01/21/2004 | EP1381359A1 Aurones as telomerase inhibitors |
| 01/21/2004 | EP1381358A1 Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp |
| 01/21/2004 | EP1381280A1 Viral vectors and their use in therapeutic methods |
| 01/21/2004 | EP1280799B1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 01/21/2004 | EP1242415B1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 01/21/2004 | EP1131083B1 Use of growth hormone releasing compounds and their antagonists for the treatment of tumors |
| 01/21/2004 | EP1126852B1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 01/21/2004 | EP0981366B1 Selective mmp inhibitors having reduced side-effects |
| 01/21/2004 | EP0787009B1 Cancer inhibitory peptides |
| 01/21/2004 | CN1469875A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469874A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469872A A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidine-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b] thiophene hydrochloride |
| 01/21/2004 | CN1469867A Novel phenylalanine derivatives |
| 01/21/2004 | CN1469865A Pyrazole derivatives for the treatment of viral diseases |
| 01/21/2004 | CN1469860A Aza-amino acid derivatives (factor XA-inhibitors 15) |
| 01/21/2004 | CN1469759A Implants with a phosphazene-containing coating |
| 01/21/2004 | CN1469752A Method for treating the central nervous system by administration of IGF structural analogs |
| 01/21/2004 | CN1469749A Use of antiprogestins for the induction of apoptosis in a cell |
| 01/21/2004 | CN1469746A A retroviral immunotherapy |
| 01/21/2004 | CN1469743A 雌激素受体调节剂 Estrogen receptor modulators |
| 01/21/2004 | CN1469736A Use of a porous carrier |
| 01/21/2004 | CN1469735A Liposomal formulation of mitoxantrone |
| 01/21/2004 | CN1469734A Pharmaceutical form of administration for peptides, method for its production and use |
| 01/21/2004 | CN1469720A Radioactive emission detector with position tracking system and application in therapeutical system and treatment process |
| 01/21/2004 | CN1469711A Treatment of helicobacter with isothiocyanates |
| 01/21/2004 | CN1468957A Plasmid used as human therapeutic vaccine adjuvant |
| 01/21/2004 | CN1468956A Recombinant virus of antibody for high-efficiency expression to treat tumor and its use |
| 01/21/2004 | CN1468854A Prepn process and use of substituted pyrazole compound |
| 01/21/2004 | CN1468628A Medicine for treatnig ovarian cyst |
| 01/21/2004 | CN1468599A Prepn for local treatment of tumor and chemotherapy of lymph and its prepn process |
| 01/21/2004 | CN1468597A Continuous released medical composition |
| 01/21/2004 | CN1135236C 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists |
| 01/20/2004 | US6680375 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer |
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680337 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 01/20/2004 | US6680333 Imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |